Skip to content
2000
image of Recent Advances in Possible Treatment Options Including Herbal Remedies for the Management of Cholelithiasis

Abstract

Cholelithiasis, particularly cholesterol-bearing-stones, is one of the gastrointestinal diseases representing a substantial global health burden. The five key primary factors inducing cholesterol-bearing-stones include genetics, hepatic cholesterol hypersecretion, rapid phase transition of cholesterol, gallbladder hypomotility, and specific intestinal factors. To date, laparoscopic cholecystectomy remains the primary treatment approach for cholelithiasis patients. The various non-surgical methods, such as bile acid therapy, novel drug candidates, and herbal remedies, are detailed. Special attention is paid to the development of ursodeoxycholic acid (UDCA)-embedded formulations. Because the UDCA is a biopharmaceutical classification system class II drug, it poses the challenge of low aqueous solubility and thus, limited oral bioavailability. Additionally, promising developments in novel drug candidates (., alirocumab), probiotics, stents, and herbal treatments with purported gallstone-dissolving properties are highlighted. The development of effective non-surgical treatments like various UDCA formulations and novel drug candidates is crucial. Additionally, the integration of herbal remedies into mainstream treatment protocols could offer significant benefits. Future research should focus on optimizing these therapies and exploring personalized treatment. Furthermore, emerging curative approaches such as gene-tailored therapy hold a future direction with a concrete perspective.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128383672250805175516
2025-08-27
2025-10-19

  • From This Site

    /content/journals/cpd/10.2174/0113816128383672250805175516
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Tazuma S. Unno M. Igarashi Y. Evidence-based clinical practice guidelines for cholelithiasis 2016. J. Gastroenterol. 2017 52 3 276 300 10.1007/s00535‑016‑1289‑7 27942871
    [Google Scholar]
  2. Wang D.Q-H. Portincasa P. Wang H.H. Bile Formation and Pathophysiology of Gallstones Encycl Gastroenterol. 2nd Ed Amsterdam, Netherlands Elsevier 2019 287 306
    [Google Scholar]
  3. Morris-Stiff G. Sarvepalli S. Hu B. The natural history of asymptomatic gallstones: A longitudinal study and prediction model. Clin. Gastroenterol. Hepatol. 2023 21 2 319 327.e4 10.1016/j.cgh.2022.04.010 35513234
    [Google Scholar]
  4. Shabanzadeh D.M. Incidence of gallstone disease and complications. Curr. Opin. Gastroenterol. 2018 34 2 81 89 10.1097/MOG.0000000000000418 29256915
    [Google Scholar]
  5. Stinton L.M. Shaffer E.A. Epidemiology of gallbladder disease: Cholelithiasis and cancer. Gut Liver 2012 6 2 172 187 10.5009/gnl.2012.6.2.172 22570746
    [Google Scholar]
  6. Everhart J.E. Yeh F. Lee E.T. Prevalence of gallbladder disease in American Indian populations: Findings from the Strong Heart Study. Hepatology 2002 35 6 1507 1512 10.1053/jhep.2002.33336 12029637
    [Google Scholar]
  7. e S. Srikanth M.S. Shreyas A. Recent advances, novel targets and treatments for cholelithiasis; a narrative review. Eur. J. Pharmacol. 2021 908 174376 10.1016/j.ejphar.2021.174376 34303667
    [Google Scholar]
  8. Unalp-Arida A. Ruhl C.E. Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the US. Hepatology 2023 77 6 1882 1895 10.1097/HEP.0000000000000264 36631004
    [Google Scholar]
  9. Tsai C.J. Leitzmann M.F. Willett W.C. Giovannucci E.L. Long-chain saturated fatty acids consumption and risk of gallstone disease among men. Ann. Surg. 2008 247 1 95 103 10.1097/SLA.0b013e31815792c2 18156928
    [Google Scholar]
  10. Tsai C.J. Leitzmann M.F. Willett W.C. Giovannucci E.L. Long-term intake of trans-fatty acids and risk of gallstone disease in men. Arch. Intern. Med. 2005 165 9 1011 1015 10.1001/archinte.165.9.1011 15883239
    [Google Scholar]
  11. Messing B. Bories C. Kunstlinger F. Bernier J.J. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis? Gastroenterology 1983 84 5 1012 1019 10.1016/0016‑5085(83)90204‑4 6403401
    [Google Scholar]
  12. Wirth J. Joshi A.D. Song M. A healthy lifestyle pattern and the risk of symptomatic gallstone disease: Results from 2 prospective cohort studies. Am. J. Clin. Nutr. 2020 112 3 586 594 10.1093/ajcn/nqaa154 32614416
    [Google Scholar]
  13. Portincasa P. Di Ciaula A. de Bari O. Garruti G. Palmieri V.O. Wang D.Q-H. Management of gallstones and its related complications. Expert Rev. Gastroenterol. Hepatol. 2016 10 1 93 112 10.1586/17474124.2016.1109445 26560258
    [Google Scholar]
  14. Wang D.Q.H. Neuschwander-Tetri B.A. Portincasa P. Pandak W.M. Interactions between bile acids and nuclear receptors and their effects on lipid metabolism and liver diseases. J. Lipids 2012 2012 1 2 10.1155/2012/560715 22593829
    [Google Scholar]
  15. Khanuja B. Cheah Y.C. Hunt M. Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc. Natl. Acad. Sci. USA 1995 92 17 7729 7733 10.1073/pnas.92.17.7729 7644485
    [Google Scholar]
  16. Wang J. Mitsche M.A. Lütjohann D. Cohen J.C. Xie X.S. Hobbs H.H. Relative roles of ABCG5/ABCG8 in liver and intestine. J. Lipid Res. 2015 56 2 319 330 10.1194/jlr.M054544 25378657
    [Google Scholar]
  17. Sun H. Warren J. Yip J. Factors influencing gallstone formation: A review of the literature. Biomolecules 2022 12 4 550 10.3390/biom12040550 35454138
    [Google Scholar]
  18. Lee M.H. Lu K. Hazard S. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 2001 27 1 79 83 10.1038/83799 11138003
    [Google Scholar]
  19. Wang D. Wang H. Two gallstone (Lith) genes, Lith9 and Lith18, produces a synergistic effect in enhancing cholelithogenesis by promoting hepatic secretion of biliary cholesterol in female mice. Physiology 2023 38 S1 5730554 10.1152/physiol.2023.38.S1.5730554
    [Google Scholar]
  20. Stender S. Frikke-Schmidt R. Nordestgaard B.G. Tybjærg-Hansen A. The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease. J. Am. Coll. Cardiol. 2014 63 20 2121 2128 10.1016/j.jacc.2013.12.055 24657701
    [Google Scholar]
  21. Dietschy J.M. Turley S.D. Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 1993 34 10 1637 1659 10.1016/S0022‑2275(20)35728‑X 8245716
    [Google Scholar]
  22. Chiang J.Y.L. Ferrell J.M. Wu Y. Boehme S. Bile acid and cholesterol metabolism in atherosclerotic cardiovascular disease and therapy. Cardiol. Plus 2020 5 4 159 170 10.4103/2470‑7511.305419 34350368
    [Google Scholar]
  23. Fuchs C.D. Paumgartner G. Wahlström A. Metabolic preconditioning protects BSEP/ABCB11−/− mice against cholestatic liver injury. J. Hepatol. 2017 66 1 95 101 10.1016/j.jhep.2016.08.017 27593105
    [Google Scholar]
  24. Deng F. Bae Y.H. Bile acid transporter-mediated oral drug delivery. J. Control. Release 2020 327 100 116 10.1016/j.jconrel.2020.07.034 32711025
    [Google Scholar]
  25. Oswald S. Organic anion transporting polypeptide (OATP) transporter expression, localization and function in the human intestine. Pharmacol. Ther. 2019 195 39 53 10.1016/j.pharmthera.2018.10.007 30347208
    [Google Scholar]
  26. Wang D.Q. Carey M.C. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: Influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing systems. J. Lipid Res. 1996 37 3 606 630 10.1016/S0022‑2275(20)37603‑3 8728323
    [Google Scholar]
  27. Wang H.H. Portincasa P. Liu M. Tso P. Samuelson L.C. Wang D.Q.H. Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2010 1801 2 138 146 10.1016/j.bbalip.2009.10.003 19836465
    [Google Scholar]
  28. Portincasa P. Di Ciaula A. Wang H.H. Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology 2008 47 6 2112 2126 10.1002/hep.22204 18506897
    [Google Scholar]
  29. Portincasa P. Moschetta A. Palasciano G. Cholesterol gallstone disease. Lancet 2006 368 9531 230 239 10.1016/S0140‑6736(06)69044‑2 16844493
    [Google Scholar]
  30. Lammert F Gurusamy K Ko CW Gallstones. Nat Rev Dis Primers 2016 2 10.1038/nrdp.2016.24
    [Google Scholar]
  31. Cuschieri A. Non-surgical options for the management of gallstone disease: An overview. Surg. Endosc. 1990 4 3 127 131 10.1007/BF02336587 2148441
    [Google Scholar]
  32. Fraquelli M. Casazza G. Conte D. Colli A. Non-steroid anti-inflammatory drugs for biliary colic. Cochrane Database Syst. Rev. 2016 9 9 CD006390 27610712
    [Google Scholar]
  33. Soper N.J. Stockmann P.T. Dunnegan D.L. Ashley S.W. Laparoscopic cholecystectomy. The new ‘gold standard’? Arch. Surg. 1992 127 8 917 921 10.1001/archsurg.1992.01420080051008 1386505
    [Google Scholar]
  34. He Y.G. Gao M.F. Li J. Cystic duct dilation through endoscopic retrograde cholangiopancreatography for treatment of gallstones and choledocholithiasis: Six case reports and review of literature. World J. Clin. Cases 2021 9 3 736 747 10.12998/wjcc.v9.i3.736 33553415
    [Google Scholar]
  35. Carr-Locke D.L. Therapeutic role of ERCP in the management of suspected common bile duct stones. Gastrointest. Endosc. 2002 56 6 S170 S174 10.1016/S0016‑5107(02)70006‑0 12447262
    [Google Scholar]
  36. Oak J.H. Paik C.N. Chung W.C. Lee K.M. Yang J.M. Risk factors for recurrence of symptomatic common bile duct stones after cholecystectomy. Gastroenterol. Res. Pract. 2012 2012 1 6 10.1155/2012/417821 22991508
    [Google Scholar]
  37. Salen G. Colalillo A. Verga D. Bagan E. Tint G.S. Shefer S. Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans. Gastroenterology 1980 78 6 1412 1418 10.1016/S0016‑5085(19)30493‑7 7372061
    [Google Scholar]
  38. Iser J.H. Dowling R.H. Mok H.Y.I. Bell G.D. Chenodeoxycholic acid treatment of gallstones. A follow-up report and analysis of factors influencing response to therapy. N. Engl. J. Med. 1975 293 8 378 383 10.1056/NEJM197508212930804 1152936
    [Google Scholar]
  39. Hofmann A.F. Medical dissolution of gallstones by oral bile acid therapy. Am. J. Surg. 1989 158 3 198 204 10.1016/0002‑9610(89)90252‑3 2672842
    [Google Scholar]
  40. Hall L. Halle-Smith J. Evans R. Ursodeoxycholic acid in the management of symptomatic gallstone disease: Systematic review and clinician survey. BJS Open 2023 7 2 zrac152 10.1093/bjsopen/zrac152 36952251
    [Google Scholar]
  41. Swell L. Bell C.C. Gregory D.H. Vlahcevic Z.R. The cholesterol saturation index of human bile. Am. J. Dig. Dis. 1974 19 3 261 265 10.1007/BF01072543 4825578
    [Google Scholar]
  42. Brass E.P. Stelten B.M.L. Verrips A. Cerebrotendinous xanthomatosis‐associated diarrhea and response to chenodeoxycholic acid treatment. JIMD Rep. 2020 56 1 105 111 10.1002/jmd2.12163 33204601
    [Google Scholar]
  43. Sharma A. Shanti H. Nageswaran H. Best L.M.J. Patel A.G. Role of ursodeoxycholic acid in the prevention of gallstones formation in bariatric patients—a systematic review and meta-analysis of randomised trials. Obes. Surg. 2023 33 12 4115 4124 10.1007/s11695‑023‑06893‑9 37872257
    [Google Scholar]
  44. Portincasa P. Ciaula A.D. Bonfrate L. Wang D.Q. Therapy of gallstone disease: What it was, what it is, what it will be. World J. Gastrointest. Pharmacol. Ther. 2012 3 2 7 20 10.4292/wjgpt.v3.i2.7 22577615
    [Google Scholar]
  45. Kim J. Jung D.H. Rhee H. Choi S-H. Sung M.J. Choi W.S. Improvement of bioavailability of water insoluble drugs: Estimation of intrinsic bioavailability (Short Communication). Korean J. Chem. Eng. 2008 25 1 171 175 10.1007/s11814‑008‑0031‑4
    [Google Scholar]
  46. Walker S. Rudolph G. Raedsch R. Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992 102 3 810 815 10.1016/0016‑5085(92)90162‑R 1537519
    [Google Scholar]
  47. Lee J. Lee C.H. Lee J.G. Jeon S.Y. Choi M.K. Song I.S. Enhancing dissolution and oral bioavailability of ursodeoxycholic acid with a spray-dried pH-modified extended release formulation. Pharmaceutics 2022 14 5 1037 10.3390/pharmaceutics14051037 35631622
    [Google Scholar]
  48. Zappaterra F. Costa S. Summa D. Glyceric prodrug of ursodeoxycholic acid (UDCA): Novozym 435-catalyzed synthesis of UDCA-monoglyceride. Molecules 2021 26 19 5966 10.3390/molecules26195966 34641510
    [Google Scholar]
  49. Xie Y. Chen Z. Su R. Preparation and optimization of amorphous ursodeoxycholic acid nano-suspensions by nanoprecipitation based on acid-base neutralization for enhanced dissolution. Curr. Drug Deliv. 2017 14 4 483 491 27593183
    [Google Scholar]
  50. Li Y. Wang Y. Yue P.F. A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production – a case study with ursodeoxycholic acid. Pharm. Dev. Technol. 2014 19 6 662 670 10.3109/10837450.2013.819015 23869484
    [Google Scholar]
  51. Yue P.F. Yuan H.L. Liu Y. Han J. Teng P-M. Preparation and Characterization of Ursodeoxycholic Acid Nanosuspension. J. Dispers. Sci. Technol. 2012 33 7 965 969 10.1080/01932691.2011.590424
    [Google Scholar]
  52. Ma Y.Q. Li G. Xu J.H. Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. Pharm. Dev. Technol. 2014 19 3 363 372 10.3109/10837450.2013.788517 23634754
    [Google Scholar]
  53. Choi G. Lee J.H. Oh Y.J. Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid. Int. J. Pharm. 2010 402 1-2 117 122 10.1016/j.ijpharm.2010.09.039 20933070
    [Google Scholar]
  54. Okonogi S. Yonemochi E. Oguchi T. Puttipipatkhachorn S. Yamamoto A.K. Enhanced dissolution of ursodeoxycholic acid from the solid dispersion. Drug Dev. Ind. Pharm. 1997 23 11 1115 1121 10.3109/03639049709150502
    [Google Scholar]
  55. Yue P.F. Yuan H.L. Xie H. Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. Drug Dev. Ind. Pharm. 2008 34 7 708 718 10.1080/03639040701842477 18612911
    [Google Scholar]
  56. Scalia S. Giunchedi P. Pazzi P. Conte U. Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose. J. Pharm. Pharmacol. 2000 52 4 383 388 10.1211/0022357001774129 10813547
    [Google Scholar]
  57. Vandelli M.A. Salvioli G. Mucci A. Panini R. Malmusi L. Forni F. 2-Hydroxypropyl-β-cyclodextrin complexation with ursodeoxycholic acid. Int. J. Pharm. 1995 118 1 77 83 10.1016/0378‑5173(94)00342‑3
    [Google Scholar]
  58. Panini R. Vandelli M.A. Forni F. Pradelli J.M. Salvioli G. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-β-cyclodextrin complexation in healthy volunteers. Pharmacol. Res. 1995 31 3-4 205 209 10.1016/1043‑6618(95)80019‑0 7630860
    [Google Scholar]
  59. Mulagha E. Fromm H. Extracorporeal shock wave lithotripsy of gallstones revisited: Current status and future promises. J. Gastroenterol. Hepatol. 2000 15 3 239 243 10.1046/j.1440‑1746.2000.02094.x 10764022
    [Google Scholar]
  60. Lanzini A. Northfield T.C. Pharmacological treatment of gallstones. Practical guidelines. Drugs 1994 47 3 458 470 10.2165/00003495‑199447030‑00006 7514975
    [Google Scholar]
  61. Shen S. Li N. Ye X. Effect of tert-butyl acetate and ethyl butyrate on the dissolution of gallbladder cholesterol stones. Chinese J Hepatobiliary Surg 2023 29 3 209 213
    [Google Scholar]
  62. Janowitz P. Schumacher K.A. Swobodnik W. Kratzer W. Tudyka J. Wechsler J.G. Transhepatic topical dissolution of gallbladder stones with MTBE and EDTA. Dig. Dis. Sci. 1993 38 11 2121 2129 10.1007/BF01297094 8223089
    [Google Scholar]
  63. Chen Z. Shao W. Li Y. Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARα-mediated CYP7A1 activation. Metabolism 2024 152 155774 10.1016/j.metabol.2023.155774 38191052
    [Google Scholar]
  64. Han F. Zhao T. Zhang Y. Discovery and exploration of novel somatostatin receptor subtype 5 (SSTR5) antagonists for the treatment of cholesterol gallstones. Eur. J. Med. Chem. 2024 264 116017 10.1016/j.ejmech.2023.116017 38070432
    [Google Scholar]
  65. Shen S. Huang D. Qian S. Hyodeoxycholic acid attenuates cholesterol gallstone formation via modulation of bile acid metabolism and gut microbiota. Eur. J. Pharmacol. 2023 955 175891 10.1016/j.ejphar.2023.175891 37429516
    [Google Scholar]
  66. Ye X. Shen S. Xu Z. Sodium butyrate alleviates cholesterol gallstones by regulating bile acid metabolism. Eur. J. Pharmacol. 2021 908 174341 10.1016/j.ejphar.2021.174341 34273384
    [Google Scholar]
  67. Oh J.K. Kim Y.R. Lee B. Choi Y.M. Kim S.H. Prevention of cholesterol gallstone formation byLactobacillus acidophilus ATCC 43121 andLactobacillus fermentum MF27 in lithogenic diet-inducedmice. Food Sci. Anim. Resour. 2021 41 2 343 352 10.5851/kosfa.2020.e93 33987554
    [Google Scholar]
  68. Chang Y. Lin H.M. Chi K.Y. Lin W.Y. Chou T.C. Association between statin use and risk of gallstone disease and cholecystectomy: A meta-analysis of 590,086 patients. PeerJ 2023 11 15149 10.7717/peerj.15149 37051411
    [Google Scholar]
  69. Ahmed M.H. Hamad M.A. Routh C. Connolly V. Statins as potential treatment for cholesterol gallstones: An attempt to understand the underlying mechanism of actions. Expert Opin. Pharmacother. 2011 12 17 2673 2681 10.1517/14656566.2011.629995 22043827
    [Google Scholar]
  70. Bertolotti M. Gabbi C. Anzivino C. Decreased hepatic expression of PPAR‐γ coactivator‐1 in cholesterol cholelithiasis. Eur. J. Clin. Invest. 2006 36 3 170 175 10.1111/j.1365‑2362.2006.01607.x 16506961
    [Google Scholar]
  71. Portincasa P. Di Ciaula A. Wang H. Moschetta A. Wang D. Medicinal treatments of cholesterol gallstones: Old, current and new perspectives. Curr. Med. Chem. 2009 16 12 1531 1542 10.2174/092986709787909631 19355905
    [Google Scholar]
  72. Jang S.I. Fang S. Kim K.P. Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice. Sci. Rep. 2019 9 1 12740 10.1038/s41598‑019‑49095‑z 31484954
    [Google Scholar]
  73. Zhang Z. Du Z. Liu Q. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity. Metabolism 2021 118 154728 10.1016/j.metabol.2021.154728 33581130
    [Google Scholar]
  74. DeLeon C. Wang H.H. Gunn J. A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice. J. Lipid Res. 2020 61 5 767 777 10.1194/jlr.RA119000592 32127396
    [Google Scholar]
  75. Cheng S. Zou M. Liu Q. Activation of constitutive androstane receptor prevents cholesterol gallstone formation. Am. J. Pathol. 2017 187 4 808 818 10.1016/j.ajpath.2016.12.013 28283178
    [Google Scholar]
  76. Gao Q. Huang C. Sun B. Fabrication and characterization of metal stent coating with drug-loaded nanofiber film for gallstone dissolution. J. Biomater. Appl. 2016 31 5 784 796 10.1177/0885328216671239 27698255
    [Google Scholar]
  77. Yang X. Wang B.C. Zhang X. Evaluation of Lysimachia christinae Hance extracts as anticholecystitis and cholagogic agents in animals. J. Ethnopharmacol. 2011 137 1 57 63 10.1016/j.jep.2011.04.029 21524697
    [Google Scholar]
  78. Liu S. Luorong Q. Hu K. Aqueous extract of Lysimachia christinae hance prevents cholesterol gallstone in mice by affecting the intestinal microflora. J. Microbiol. Biotechnol. 2021 31 9 1272 1280 10.4014/jmb.2106.06043 34261853
    [Google Scholar]
  79. Deng J. Ren M. Dai X. Lysimachia christinae Hance regresses preestablished cholesterol gallstone in mice. J. Ethnopharmacol. 2015 166 102 108 10.1016/j.jep.2015.03.031 25794804
    [Google Scholar]
  80. Li Y. Chen Y. Sun-Waterhouse D. The potential of dandelion in the fight against gastrointestinal diseases: A review. J. Ethnopharmacol. 2022 293 115272 10.1016/j.jep.2022.115272 35405251
    [Google Scholar]
  81. Zhuang Q. Cheng J. Xia J. Gypenosides prevent and dissolve cholesterol gallstones by modulating the homeostasis of cholesterol and bile acids. Front. Med. 2022 9 818144 10.3389/fmed.2022.818144 35445045
    [Google Scholar]
  82. Sharma B. Sethi B. Raj S. Poddar R. Prasad A. Sharma S.R. Exploration of molecular interactions between scoparone and associated compounds with Constitutive androstane receptor (CAR) leading to gallstone prevention: An in silico investigation. J. Biomol. Struct. Dyn. 2024 42 2 960 976 10.1080/07391102.2023.2198010 37096767
    [Google Scholar]
  83. Hussain M.S. Chandrasekhara N. Influence of curcumin and capsaicin on cholesterol gallstone induction in hamsters and mice. Nutr. Res. 1993 13 3 349 357 10.1016/S0271‑5317(05)80431‑2
    [Google Scholar]
  84. Hussain M.S. Chandrasekhara N. Effect of curcumin and capsaicin on the regression of preestablished cholesterol gallstones in mice. Nutr. Res. 1994 14 10 1561 1574 10.1016/S0271‑5317(05)80234‑9
    [Google Scholar]
  85. Zhuang Q. Ye X. Shen S. Astragalus Polysaccharides ameliorate diet-induced gallstone formation by modulating synthesis of bile acids and the gut microbiota. Front. Pharmacol. 2021 12 701003 10.3389/fphar.2021.701003 34276384
    [Google Scholar]
  86. Reddy R.L.R. Srinivasan K. Fenugreek seeds reduce atherogenic diet-induced cholesterol gallstone formation in experimental mice. Can. J. Physiol. Pharmacol. 2009 87 11 933 943 10.1139/Y09‑084 19935901
    [Google Scholar]
  87. Reddy R.L.R. Srinivasan K. Dietary fenugreek seed regresses preestablished cholesterol gallstones in mice. Can. J. Physiol. Pharmacol. 2009 87 9 684 693 10.1139/Y09‑062 19794519
    [Google Scholar]
  88. Vidyashankar S. Sambaiah K. Srinivasan K. Dietary garlic and onion reduce the incidence of atherogenic diet-induced cholesterol gallstones in experimental mice. Br. J. Nutr. 2009 101 11 1621 1629 10.1017/S0007114508118748 18983715
    [Google Scholar]
  89. Vidyashankar S. Sambaiah K. Srinivasan K. Regression of preestablished cholesterol gallstones by dietary garlic and onion in experimental mice. Metabolism 2010 59 10 1402 1412 10.1016/j.metabol.2009.12.032 20153000
    [Google Scholar]
  90. Vidyashankar S. Sambaiah K. Srinivasan K. Effect of dietary garlic and onion on biliary proteins and lipid peroxidation which influence cholesterol nucleation in bile. Steroids 2010 75 3 272 281 10.1016/j.steroids.2010.01.003 20079366
    [Google Scholar]
  91. Fang B.J. Shen J.Y. Zhang H. Zhou S. Lyu C.Z. Xie Y.Q. Albiflorin Granule significantly decreased the cholesterol gallstone formation by the regulation of insulin transduction signal. Asian Pac. J. Trop. Med. 2016 9 9 877 881 10.1016/j.apjtm.2016.07.010 27633302
    [Google Scholar]
  92. Suresh S. Singh S.A. Vellapandian C. Preclinical evaluation of Hibiscus cannabinus Linn. in the treatment of urolithiasis and cholelithiasis. Digit. Chin. Med. 2023 6 2 189 197 10.1016/j.dcmed.2023.07.008
    [Google Scholar]
  93. Ren S. Yan X. Ma J. Defatted walnut powder extract reduces cholesterol gallstones formation in C57BL/6 mice by downregulating the levels of ABCG5/8 in the liver and NPC1L1 in the intestine. J. Funct. Foods 2018 48 85 91 10.1016/j.jff.2018.06.017
    [Google Scholar]
  94. Song X.Y. Xu S. Hu J.F. Piperine prevents cholesterol gallstones formation in mice. Eur. J. Pharmacol. 2015 751 112 117 10.1016/j.ejphar.2015.01.038 25645812
    [Google Scholar]
  95. Liu M. Zhang G. Wu S. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor. J. Ethnopharmacol. 2020 255 112776 10.1016/j.jep.2020.112776 32205261
    [Google Scholar]
  96. Bais S. Patel N.J. Protective effect of Juniperus communis extract by inhibition of Pro-nucleating agents in lithogenic diet induced cholelithiasis in mice. Obes. Med. 2020 20 100288 10.1016/j.obmed.2020.100288
    [Google Scholar]
  97. Castro-Torres I.G. De la O-Arciniega M. Gallegos-Estudillo J. Naranjo-Rodríguez E.B. Domínguez-Ortíz M.Á. Raphanus sativus L. var niger as a source of Phytochemicals for the Prevention of Cholesterol Gallstones. Phytother. Res. 2014 28 2 167 171 10.1002/ptr.4964 23495001
    [Google Scholar]
  98. Tiwari S.W. Negi Sah A. Effect of apricot fruit and kernel extracts on in-vitro dissolution of cholesterol gallstones: Implication for development of potent anti-cholilithiaticc agent. Indian J Pharma Educat Res 2020 54 3 755 760 10.5530/ijper.54.3.127
    [Google Scholar]
  99. Micucci M. Ioan P. Aldini R. Castanea sativa Mill. extract contracts gallbladder and relaxes sphincter of Oddi in guinea pig: A natural approach to biliary tract motility disorders. J. Med. Food 2014 17 7 795 803 10.1089/jmf.2013.0090 24654975
    [Google Scholar]
  100. Costa CJ Nguyen MTT Vaziri H Wu GY Genetics of gallstone disease and their clinical significance: A narrative review. J Clin Transl Hepatol 2024 000 000 000 10.14218/JCTH.2023.00563 38426197
    [Google Scholar]
  101. Yang B. Liu B. Bi P. Wu T. Wang Q. Zhang J. An integrated analysis of differential miRNA and mRNA expressions in human gallstones. Mol. Biosyst. 2015 11 4 1004 1011 10.1039/C4MB00741G 25639987
    [Google Scholar]
  102. Wang Z. Zhao Y. Zhang L. Emerging trends and hot topics in the application of multi-omics in drug discovery: A bibliometric and visualized study. Curr. Pharm. Anal. 2024 21 1 20 32 10.1016/j.cpan.2024.12.001
    [Google Scholar]
  103. Mega J.L. Close S.L. Wiviott S.D. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009 360 4 354 362 10.1056/NEJMoa0809171 19106084
    [Google Scholar]
  104. Yin C.L. Ma Y.J. The regulatory mechanism of hypoxia-inducible factor 1 and its clinical significance. Curr. Mol. Pharmacol. 2024 17 1 18761429266116 10.2174/0118761429266116231123160809 38389420
    [Google Scholar]
  105. Chen J. Lin A. Luo P. Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies. Curr. Pharm. Anal. 2024 21 1 1 19 10.1016/j.cpan.2024.11.001
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128383672250805175516
Loading
Recent Advances in Possible Treatment Options Including Herbal Remedies for the Management of Cholelithiasis
Bentham Science Publishers ; https://doi.org/10.2174/0113816128383672250805175516
/content/journals/cpd/10.2174/0113816128383672250805175516
/content/journals/cpd/10.2174/0113816128383672250805175516
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: herbal medicines ; ursodeoxycholic acid ; cholesterol ; gallstones ; octreotide ; Cholelithiasis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test